SA
VLEEY logo
Valeo SE(VLEEY)
Closing price · checked 11:24 PM ETAbout this dataData status
$5.63▼-0.29 (-4.90%)
Extended:$5.63+0.00 (+0.00%)· 11:24 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Valeo SE (VLEEY)

R&D to Revenue

8.55%

Fiscal year · Period ending:

VLEEY logo

VLEEY R&D to Revenue

Latest reported8.55%
VLEEY FY R&D/Revenue (6.64% → 8.55%)
Powered by
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

VLEEY r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.

Valeo SE R&D to Revenue — Annual fiscal periods
Period endingR&D to RevenueChange
8.549%+0.86 pts
7.6912%+0.24 pts
7.4487%+0.30 pts
7.1518%+0.35 pts
6.8011%−1.49 pts
8.2867%−0.71 pts
8.9952%+0.00 pts
8.9939%+1.57 pts
7.428%−0.01 pts
7.4399%+0.51 pts
6.9307%−0.04 pts
6.9705%+0.10 pts
6.8685%+0.39 pts
6.4801%+0.02 pts
6.4593%+0.12 pts
6.3434%−0.87 pts
7.2143%−0.58 pts
7.7935%+0.90 pts
6.8944%+0.55 pts
6.3454%−0.55 pts
6.8914%+0.25 pts
6.641%—

Frequently asked questions: VLEEY r&d to revenue

What is Valeo SE (VLEEY)'s current r&d to revenue?

Valeo SE (VLEEY)'s latest reported r&d to revenue (Fiscal year) is 8.55% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for VLEEY?

Stock Alarm Pro provides 22 dated annual fiscal periods observations for Valeo SE (VLEEY)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare VLEEY's r&d to revenue to peers or set an alert?

You can open VLEEY's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on VLEEY delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.